Retatrutide (Reta GLP-3R) Research Guide: Triple Incretin Receptor Agonist Mechanism and Trial Data

Retatrutide (also sold under the research name Reta GLP-3R) is a first-in-class triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. No other peptide in clinical development activates all three of these metabolic pathways at once — and the clinical trial results have made retatrutide one of the most studied weight management compounds in modern pharmaceutical research.

This guide consolidates everything researchers need to know about retatrutide: its mechanism of action, published clinical trial data, dosage calculations, reconstitution instructions, storage, purity verification, and where to source research-grade material.

What Is Retatrutide? The Triple Agonist Explained

Retatrutide is a 39-amino acid peptide engineered to simultaneously activate three metabolic hormone receptors:

• GLP-1 (Glucagon-Like Peptide-1): Reduces appetite, slows gastric emptying, improves insulin sensitivity. This is the same pathway targeted by semaglutide (Ozempic/Wegovy).
• GIP (Glucose-Dependent Insulinotropic Polypeptide): Enhances insulin secretion, improves fat metabolism, and amplifies the effects of GLP-1 activation. This is the second pathway used by tirzepatide (Mounjaro).
• Glucagon receptor: Increases energy expenditure, promotes hepatic fat oxidation, and mobilizes fat stores for energy. This is what makes retatrutide unique — no other approved or late-stage clinical compound targets this pathway alongside GLP-1 and GIP.

The glucagon receptor component is what separates retatrutide from every other GLP-1 compound on the market. While semaglutide works through GLP-1 alone and tirzepatide adds GIP, retatrutide adds glucagon receptor activation on top of both — creating what researchers describe as a “triple agonist” approach to metabolic regulation.

Reta GLP-3R (Retatrutide) 10mg
Triple receptor agonist — Shop now

How Retatrutide Works: Three Pathways, One Peptide

Understanding why retatrutide produces stronger clinical results than single- or dual-agonist compounds requires understanding what each receptor pathway contributes:

GLP-1 Receptor Activation

The GLP-1 component is the foundation of retatrutide’s appetite suppression effects. When activated, GLP-1 receptors in the hypothalamus reduce hunger signaling, while GLP-1 receptors in the gut slow gastric emptying (making you feel full longer). This pathway also improves pancreatic beta-cell function and insulin sensitivity. Every successful weight management peptide on the market uses this pathway — retatrutide simply builds on top of it.

GIP Receptor Activation

GIP receptor activation amplifies the metabolic effects of GLP-1 in several important ways. It enhances glucose-dependent insulin secretion (reducing blood sugar spikes), improves lipid metabolism, and has emerging evidence for direct effects on adipose tissue. Tirzepatide (Mounjaro) was the first compound to prove that adding GIP to GLP-1 produces superior results to GLP-1 alone — retatrutide takes this dual-agonist approach and extends it further.

Glucagon Receptor Activation

This is retatrutide’s differentiator. Glucagon receptor activation increases resting energy expenditure — essentially raising the metabolic rate even at rest. It promotes hepatic fat oxidation (burning liver fat for energy), mobilizes stored triglycerides, and increases thermogenesis. While the GLP-1 and GIP pathways primarily reduce energy intake (appetite suppression), glucagon receptor activation increases energy output. This dual approach — eating less AND burning more — is the theoretical basis for retatrutide’s superior clinical results.

Retatrutide Clinical Trial Results

Retatrutide has produced the most impressive weight reduction data of any compound in clinical trials to date. Here are the key published results:

Phase 2 Trial (Published in NEJM, 2023)

The landmark Phase 2 trial enrolled 338 adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition. Results at 48 weeks:

• Highest dose group (12mg): Mean body weight reduction of 24.2%
• 100% of participants in the 12mg group achieved ≥5% metabolic regulation
• 83% achieved ≥15% metabolic regulation
• 63% achieved ≥20% metabolic regulation
• Significant improvements in metabolic parameters including HbA1c, fasting glucose, lipid profiles, and blood pressure

For context, these numbers surpass the published results of both semaglutide (approximately 15% in the STEP trials) and tirzepatide (approximately 22.5% in SURMOUNT-1). The 24.2% mean reduction represents an unprecedented level of efficacy for a non-surgical weight management intervention.

Phase 2 NAFLD/NASH Trial

A separate Phase 2 study investigated retatrutide’s effects on non-alcoholic fatty liver disease (NAFLD), now called metabolic dysfunction-associated steatotic liver disease (MASLD). Results showed:

• Significant reductions in liver fat content
• Improvement in markers of hepatic inflammation
• Dose-dependent improvements in liver health biomarkers

The liver benefits are attributed primarily to glucagon receptor activation, which promotes hepatic fat oxidation — providing a therapeutic rationale beyond weight management alone.

Phase 3 Trials (Ongoing)

Eli Lilly (the developer) has retatrutide in multiple Phase 3 clinical trials as of 2026, including studies on obesity, type 2 diabetes, and MASLD/NASH. The compound has not yet received FDA approval but is widely considered one of the most promising late-stage weight management candidates in pharmaceutical development.

Retatrutide reported adverse events in literature in Clinical Trials

Published clinical trial data reports the following adverse events in retatrutide study participants. Reported Adverse Events in Literature were generally dose-dependent and most common during the dose-escalation phase:

Common reported adverse events in literature (>10% incidence in high-dose groups)

• Nausea: The most frequently reported side effect, typically mild-to-moderate and improving over time as subjects acclimated to the dose
• Diarrhea: GI-related, consistent with GLP-1 receptor activation
• Vomiting: More common during dose escalation phases
• Decreased appetite: Expected pharmacological effect of GLP-1 agonism
• Constipation: Related to slowed gastric motility

Less Common reported adverse events in literature

• Injection site reactions
• Dyspepsia (indigestion)
• Abdominal pain
• Increased heart rate (small, dose-dependent increase observed in some groups)

The side effect profile is broadly consistent with other GLP-1 agonists (semaglutide, tirzepatide). The dose-escalation protocol used in clinical trials — starting at lower doses and titrating up over weeks — was specifically designed to minimize GI reported adverse events in literature during the adjustment period.

Retatrutide vs Semaglutide vs Tirzepatide: Quick Comparison

For a deeper analysis of how these compounds compare across every dimension — efficacy, mechanism, reported adverse events in literature, and research trajectory — see our detailed three-way comparison guide.

Reta GLP-3R 10mg
Triple agonist


Tirz GLP-2 12mg
Dual agonist


Tesamorelin 10mg
GHRH analog

Retatrutide Dosage: Research Protocol Calculations

Clinical trial dosage data provides the framework for research protocols. The Phase 2 trial used a dose-escalation approach with the following groups:

Research Dosage Calculation Example

For a research protocol targeting 8mg weekly using a 10mg vial:

• Reconstitute 10mg vial with 1ml of bacteriostatic water
• Concentration: 10mg/ml = 10,000 mcg/ml
• Volume per 8mg dose: 0.8ml (80 units on insulin syringe)
• Vial provides: 1.25 weekly doses at 8mg

Use the calculator instead of manual math: Our free peptide reconstitution calculator handles all dosage calculations instantly. Enter your vial size, desired solvent volume, and target dose — it gives you the exact syringe volume. Over 1,800 researchers use it monthly.

How to Reconstitute Retatrutide (Reta GLP-3R)

Retatrutide reconstitution follows the same process as other lyophilized peptides:

1. Gather materials: Reta GLP-3R vial, bacteriostatic water, alcohol swabs, sterile syringes
2. Calculate solvent volume using the peptide calculator
3. Sterilize both vial stoppers with alcohol swabs and allow to air dry
4. Draw the calculated BAC water volume into a sterile syringe
5. Inject slowly along the vial wall — let the water trickle down the glass, never spray directly onto the powder
6. Allow to dissolve without shaking (gentle swirling is fine). Retatrutide typically dissolves within 2-5 minutes
7. Refrigerate immediately at 2-8°C after reconstitution

For comprehensive step-by-step instructions with photos and common mistakes to avoid, see our full peptide reconstitution guide.

How to Store Retatrutide

Proper storage is critical for maintaining retatrutide’s potency and ensuring reliable research results.

Lyophilized (Powder) Storage

• Room temperature: Stable for weeks to months in the sealed original vial, away from light and moisture
• Refrigerated (2-8°C): Recommended for storage beyond 30 days — significantly extends stability
• Frozen (-20°C): Ideal for long-term bulk storage; avoid repeated freeze-thaw cycles

Reconstituted (Liquid) Storage

• Refrigerated (2-8°C): 4-8 weeks when reconstituted with bacteriostatic water
• Room temperature: Significant degradation within days — never leave reconstituted peptides unrefrigerated

Always use bacteriostatic water (not sterile water) for reconstitution. The 0.9% benzyl alcohol preservative prevents microbial growth and extends the usable life of reconstituted peptides. For detailed storage timelines and temperature data, read our full guide: How Long Do Peptides Last at Room Temperature?

Purity and Third-Party Testing

Retatrutide’s 39-amino acid chain makes it one of the more complex peptides to synthesize, which means purity verification is especially important. Low-purity preparations may contain truncated sequences, deletion peptides, or oxidized variants that can confound research results.

Every batch of Prax Peptides Reta GLP-3R is independently verified via HPLC and mass spectrometry, with certificates of analysis available for every lot. View current batch results on our third-party lab reports page.

For a deeper understanding of why purity matters and how to read a certificate of analysis, see: Why 99.8%+ Peptide Purity Matters.

Research Sourcing for Research-Grade Retatrutide

When sourcing retatrutide for research, the three non-negotiable quality indicators are:

1. Third-party HPLC testing with publicly available certificates of analysis (not just claims of “high purity”)
2. Mass spectrometry verification confirming the correct molecular weight and sequence identity
3. Transparent sourcing — the vendor should be open about their synthesis and QC processes

Prax Peptides publishes all batch test results, ships with individual certificates of analysis, and offers free shipping on orders over $150. Our Reta GLP-3R is available in 10mg vials — the standard research quantity.

Shop Retatrutide and Related Weight Management Research Peptides

Reta GLP-3R 10mg
Triple agonist

Tirz GLP-2 12mg
Dual agonist

Tesamorelin 10mg
GHRH analog

Tesofensine 500mcg
Oral weight mgmt

MOTS-C 10mg
Metabolic peptide

SLU-PP-332
Exercise mimetic

BAC Water 30ml
Reconstitution solvent

Frequently Asked Questions

Is retatrutide FDA approved?

No. Retatrutide is currently in Phase 3 clinical trials conducted by Eli Lilly. It has not been approved by the FDA for any medical use. It is available as a research chemical for in vitro and preclinical research only.

What makes retatrutide different from semaglutide and tirzepatide?

Retatrutide is a triple agonist — it activates GLP-1, GIP, and glucagon receptors simultaneously. Semaglutide targets only GLP-1, and tirzepatide targets GLP-1 + GIP. The glucagon receptor component increases energy expenditure and promotes liver fat oxidation, which is unique to retatrutide among compounds in late-stage clinical development.

How much metabolic regulation did retatrutide produce in clinical trials?

The Phase 2 clinical trial published in the New England Journal of Medicine reported a mean body weight reduction of 24.2% in the highest dose group (12mg weekly) over 48 weeks. This exceeds published results from both semaglutide (~15%) and tirzepatide (~22.5%) trials.

What are the reported adverse events in literature of retatrutide?

The most common reported adverse events in literature reported in clinical trials are gastrointestinal — nausea, diarrhea, vomiting, and decreased appetite. These are consistent with other GLP-1 agonists and were most common during dose escalation. A gradual titration protocol significantly reduced the incidence and severity of GI reported adverse events in literature.

How do I reconstitute Reta GLP-3R?

Add bacteriostatic water slowly along the inside wall of the vial. Do not shake. Use our peptide calculator to determine exact solvent volumes and dosing. See the full reconstitution section above for step-by-step instructions.

Can I take retatrutide orally?

Retatrutide is a 39-amino acid peptide that would be largely degraded by gastric enzymes if taken orally. All clinical trial data is from subcutaneous injection. Unlike BPC-157 (which has demonstrated oral stability), retatrutide must be administered parenterally for biological activity.

What is Reta GLP-3R?

Reta GLP-3R is the research product name for retatrutide — it stands for Retatrutide GLP-3Receptor (referring to its activity on all three incretin/glucagon receptor types). It is the same compound studied in Eli Lilly’s clinical trials, sold as a research chemical.

Disclaimer: Retatrutide (Reta GLP-3R) is sold for research purposes only. This content is for educational and informational purposes and does not constitute medical advice. Retatrutide is not approved by the FDA for human use. Consult applicable regulations in your jurisdiction before purchasing research peptides.